Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro

Cancer Immunology, Immunotherapy

Volumn 60, Issue 3, 2011, Pages 361-370

  Li, Haishan ^a   Pauza, C David ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Gammadelta; Immunotherapy; Metabolism; Rapamycin; T cell; Vdelta2

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; S6 KINASE1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CHEMOKINE RECEPTOR CCR5; IL2RA PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; KINETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VDELTA2 T LYMPHOCYTE; ANTIGEN PRESENTING CELL; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LYMPHOCYTE ACTIVATION; METABOLISM; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGEN-PRESENTING CELLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, CCR5; SIGNAL TRANSDUCTION; SIROLIMUS; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 79953814668     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0945-7     Document Type: Article

References (46)

1. Carding SR, Egan PJ (2002) Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2(5):336-345. doi:10.1038/nri797 (Pubitemid 37328756)
2. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, Pauza CD, Strome SE, Chapoval AI (2008) Isopentenyl pyrophosphate-activated cd56 + gamma}{delta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 14(13):4232-4240. doi:10.1158/1078- 0432.CCR-07-4912
3. Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan PL, Lam KT, Peiris JS, Lau YL, Tu W (2009) Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis 200(6):858-865. doi:10.1086/605413
4. Bonneville M, Scotet E (2006) Human vgamma9vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18(5):539-546. doi:10.1016/j.coi.2006.07.002 (Pubitemid 44311448)
5. Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, Misiano G, Dieli F, Salerno A (2008) Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther 8(7):875-883. doi:10.1517/14712598.8.7.875 (Pubitemid 352007000)
6. Wang L, Das H, Kamath A, Bukowski JF (2001) Human v gamma 2v delta 2 T cells produce IFN-gamma and TNF-alpha with an on/off/on cycling pattern in response to live bacterial products. J Immunol 167(11):6195-6201 (Pubitemid 33081547)
7. Li H, Luo K, Pauza CD (2008) TNF-alpha is a positive regulatory factor for human vgamma2 vdelta2 T cells. J Immunol 181(10):7131-7137
8. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A (2005) Phosphostim-activated gamma delta t cells kill autologous metastatic renal cell carcinoma. J Immunol 174(3):1338-1347
9. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD (2005) Ex vivo expanded human vgamma9vdelta2 + gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 173(5):1552-1556 (Pubitemid 40524770)
10. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375(6527):155-158. doi:10.1038/375155a0
11. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384-392 (Pubitemid 30463353)
12. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200-206. doi:10.1182/blood-2002-12-3665 (Pubitemid 36759655)
13. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102(6):2310-2311. doi:10.1182/blood-2003-05-1655 (Pubitemid 37122416)
14. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC (2007) Targeting human gamma}delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15):7450-7457. doi:10.1158/0008-5472.CAN-07-0199 (Pubitemid 47206575)
15. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H (2007) Safety profile and antitumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56(4):469-476. doi:10.1007/s00262-006-0199-6 (Pubitemid 46204533)
16. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Negrier S (2008) Phase-i study of innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599-1609. doi:10.1007/s00262-008-0491-8
17. Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M, Tiollier J, Romagne F (2005) In vivo immunomanipulation of v gamma 9v delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 175(8):5471-5480
18. Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (ay-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28(10):721-726
19. Saunders RN, Metcalfe MS, Nicholson ML (2001) Rapamycin in transplantation: a review of the evidence. Kidney Int 59(1):3-16. doi:10.1046/j.1523-1755.2001.00460.x
20. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E (2004) Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurininhibitor therapy. Transpl Int 17(4):215-220. doi:10.1007/s00147-004-0700-0 (Pubitemid 38758188)
21. Izzedine H, Brocheriou I, Frances C (2005) Post-transplantation proteinuria and sirolimus. N Engl J Med 353(19):2088-2089. doi: 10.1056/NEJM200511103531922
22. Singer SJ, Tiernan R, Sullivan EJ (2000) Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343(24):1815-1816
23. Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-Bruneel MF, Varet B, Kreis H, Morelon E (2005) Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80(9):1212-1219 (Pubitemid 41746799)
24. Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9(5):324-337. doi:10.1038/nri2546
25. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM (2006) Ablation in mice of the mTORc components raptor, rictor, or mlst8 reveals that mTORc2 is required for signaling to Akt-foxo and pkcalpha, but not s6k1. Dev Cell 11(6):859-871. doi:10.1016/j.devcel.2006.10.007 (Pubitemid 44804279)
26. Weichhart T, Saemann MD (2009) The multiple facets of mTOR in immunity. Trends Immunol 30(5):218-226. doi:10.1016/j.it2009.02.002
27. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, Pulendran B (2008) Toll-like receptor-mediated induction of type i interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive pi(3)k-mTOR-p70s6k pathway. Nat Immunol 9(10):1157-1164. doi:10.1038/ni.1645
28. Turnquist HR, Cardinal J, Macedo C, Rosborough BR, Sumpter TL, Geller DA, Metes D, Thomson AW (2010) mTOR and GSK-3 shape the CD4+ T cell stimulatory and differentiation capacity of myeloid dc following exposure to LPS. Blood. doi: 10.1182/blood-2009-10-251488
29. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, Cantrell DA (2008) Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 9(5):513-521. doi:10.1038/ni.1603 (Pubitemid 351560520)
30. Haxhinasto S, Mathis D, Benoist C (2008) The Akt-mTOR axis regulates de novo differentiation of CD4+ FOXp3+ cells. J Exp Med 205(3):565-574. doi:10.1084/jem.20071477 (Pubitemid 351439304)
31. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R (2009) Mtor regulates memory CD8 T cell differentiation. Nature 460(7251):108-112. doi:10.1038/nature08155
32. Gilliam BL, Heredia A, Devico A, Le N, Bamba D, Bryant JL, Pauza CD, Redfield RR (2007) Rapamycin reduces ccr5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 21(15):2108-2110. doi:10.1097/QAD.0b013e3282f02a4f (Pubitemid 47462163)
33. Papadopoulos NG, Dedoussis GV, Spanakos G, Gritzapis AD, Baxevanis CN, Papamichail M (1994) An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 177(1-2):101-111
34. Li H, Pauza CD (2009) Effects of 15-deoxy-delta12, 14-prostaglandin j2 (15d-pgj2) and rosiglitazone on human gammadelta2 t cells. PLoS One 4(11):e7726. doi:10.1371/journal.pone.0007726
35. Murooka TT, Wong MM, Rahbar R, Majchrzak-Kita B, Proudfoot AE, Fish EN (2006) Ccl5-ccr5-mediated apoptosis in t cells: requirement for glycosaminoglycan binding and ccl5 aggregation. J Biol Chem 281(35):25184-25194. doi:10.1074/jbc.M603912200 (Pubitemid 44401905)
36. Tikhonov I, Deetz CO, Paca R, Berg S, Lukyanenko V, Lim JK, Pauza CD (2006) Human vgamma2vdelta2 T cells contain cytoplasmic rantes. Int Immunol 18(8):1243-1251. doi:10.1093/intimm/dxl055 (Pubitemid 44349299)
37. Cory S, Huang DC, Adams JM (2003) The bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22(53):8590-8607. doi:10.1038/sj.onc.1207102 (Pubitemid 38028528)
38. Brandes M, Willimann K, Moser B (2005) Professional antigenpresentation function by human gammadelta T cells. Science 309(5732):264-268. doi:10.1126/science.1110267 (Pubitemid 40967855)
39. reg) and effector T cells to rapamycin. PLoS One 4 (6):e5994. doi:10.1371/journal.pone. 0005994
40. Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine rantes. Nature 347(6294):669-671. doi:10.1038/347669a0 (Pubitemid 20356243)
41. Mellado M, de Ana AM, Moreno MC, Martinez C, Rodriguez-Frade JM (2001) A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol 11(9):691-696 (Pubitemid 32418165)
42. Cartier L, Dubois-Dauphin M, Hartley O, Irminger-Finger I, Krause KH (2003) Chemokine-induced cell death in ccr5-expressing neuroblastoma cells. J Neuroimmunol 145(1-2):27-39 (Pubitemid 37485965)
43. Algeciras-Schimnich A, Vlahakis SR, Villasis-Keever A, Gomez T, Heppelmann CJ, Bou G, Paya CV (2002) Ccr5 mediates fasand caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS 16(11):1467-1478 (Pubitemid 34804211)
44. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A (2001) Rapamycin increases the cellular concentration of the bcl-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 37(16):2121-2128 (Pubitemid 32938119)
45. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD (2008) Impacts of HIV infection on vgamma2vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in aids. J Leukoc Biol 84(2):371-379. doi:10.1189/jlb.1207847
46. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW (2007) Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 178(11):7018-7031 (Pubitemid 46847428)